The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

NEW YORK – Bluebird Bio on Friday said it will be purchased by funds managed by investment firms Carlyle and SK Capital Partners, after which it will become a privately held company. Under the terms ...

Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.

The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

NEW YORK – Cel-Sci on Thursday said it will initiate a Phase III registrational trial of its immunotherapy Multikine (leukocyte interleukin injection) in newly diagnosed, locally advanced head and ...

Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...

NEW YORK – Boehringer Ingelheim on Thursday said it and its partners have launched a first-in-human Phase I/II trial, dubbed LENTICLAIR 1, to test an investigational gene therapy for cystic fibrosis ...